Status: Bibliographieeintrag
Standort: ---
Exemplare:
---
| |  Online-Ressource |
|---|
| Verfasst von: | Korkmaz-İçöz, Sevil [VerfasserIn]  |
|---|
| | Radovits, Tamás [VerfasserIn] |
|---|
| | Szabó, Gábor [VerfasserIn] |
|---|
| Titel: | Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure |
|---|
| Verf.angabe: | Sevil Korkmaz‐Icöz, Tamás Radovits, Gábor Szabó |
|---|
| Jahr: | 2018 |
|---|
| Jahr des Originals: | 2017 |
|---|
| Umfang: | 9 S. |
|---|
| Teil: | volume:175 |
|---|
| | year:2018 |
|---|
| | number:2 |
|---|
| | pages:223-231 |
|---|
| | extent:9 |
|---|
| Fussnoten: | First published: 18 February 2017 ; Gesehen am 24.10.2018 |
|---|
| Titel Quelle: | Enthalten in: British journal of pharmacology |
|---|
| Ort Quelle: | Malden, MA : Wiley, 1946 |
|---|
| Jahr Quelle: | 2018 |
|---|
| Band/Heft Quelle: | 175(2018), 2, Seite 223-231 |
|---|
| ISSN Quelle: | 1476-5381 |
|---|
| Abstract: | Phosphodiesterase type 5 (PDE5) selectively hydrolyses the second messenger cGMP into 5′-GMP, thereby regulating its intracellular concentrations. Dysregulation of the cGMP-dependent pathway plays a significant role in various cardiovascular diseases. Therefore, its modulation by drugs, such as PDE5 inhibitors, may represent an effective therapeutic approach. There are currently four PDE5 inhibitors available for the treatment of erectile dysfunction: sildenafil, vardenafil, tadalafil and avanafil. Sildenafil and tadalafil have also received Food and Drug Administration approval for the treatment of pulmonary arterial hypertension. This review summarizes the pharmacological aspects and clinical potential of PDE5 inhibition for the treatment of myocardial ischaemia/reperfusion injury and heart failure. Linked Articles This article is part of a themed section on Inventing New Therapies Without Reinventing the Wheel: The Power of Drug Repurposing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v175.2/issuetoc |
|---|
| DOI: | doi:10.1111/bph.13749 |
|---|
| URL: | Bitte beachten Sie: Dies ist ein Bibliographieeintrag. Ein Volltextzugriff für Mitglieder der Universität besteht hier nur, falls für die entsprechende Zeitschrift/den entsprechenden Sammelband ein Abonnement besteht oder es sich um einen OpenAccess-Titel handelt.
Volltext ; Verlag: http://dx.doi.org/10.1111/bph.13749 |
|---|
| | Volltext: https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1111/bph.13749 |
|---|
| | DOI: https://doi.org/10.1111/bph.13749 |
|---|
| Datenträger: | Online-Ressource |
|---|
| Sprache: | eng |
|---|
| K10plus-PPN: | 158226970X |
|---|
| Verknüpfungen: | → Zeitschrift |
|---|
Targeting phosphodiesterase 5 as a therapeutic option against myocardial ischaemia/reperfusion injury and for treating heart failure / Korkmaz-İçöz, Sevil [VerfasserIn]; 2018 (Online-Ressource)
68320649
